@christianrolfo
Director Division of Medical Oncology. Assoc Director Early Phase Clinical Trials The James Comprehensive Cancer Center. Professor at The OSU.Liquid Biopsy T/RT my own #liquidbiopsy #biomarkers #lungcancer #drugdevelopment
🩸🚀 New Insights in Liquid Biopsy! 🧬
The ISLB has just published a perspective article about Minimal requirement for ctDNA analysis.
🔗 Read the full article here
www.journalofliquidbiopsy.com/article/S295...
🚨Excited to represent the @islb.info at #ASCO25!
Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities!
Got questions about the society? We’ve got answers. Come to connect!🩸
@ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social
Very honored of this important recognition in my born country. Blessed to share this special moment with my family, friends and great colleagues from Argentina 🇦🇷 looking forward to continue working with @UBAonline from OSU @OhioStateMedOnc ! Thanks to all my team @rolfolab.bsky.social
📍We proudly celebrate Prof. Christian Rolfo for being awarded the honorary title of Doctor Honoris Causa by the University of Buenos Aires! 🎓✨ Congratulations on this well-deserved recognition! @christianrolfo.bsky.social @yukselurun.bsky.social @mjoseserrano.bsky.social
Thank you, @christianrolfo.bsky.social!
@swog.org #SWOGonc
New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx.
➡️ #Tepotinib showed robust efficacy regardless of biopsy type
@christianrolfo.bsky.social @oncoalert.bsky.social
🔬📈 Check out our new commentary on Selinexor (an XPO1 inhibitor) + ICIs in uveal melanoma patients in a phase 1B trial!
➡️12m OS 55 %
➡️0 % ORR
➡️manageable safety profile
@christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social #CarlosAyala
pmc.ncbi.nlm.nih.gov/articles/PMC...
Thanks Hope Foundation SWOG for the great honor to give the Robert Livingston Translational Cancer Lecture. In memory of a pioneer in thoracic research.Thanks @JhanelleGray @DrRoyHerbstYale for the opportunity.
@SupportingSWOG @OSUCCC_James @OhioStateMedOnc @OhioStateMedOnc
Today family picture with some of the 87 amazing faculty of our Division of Medical Oncology at The James CCC. Very honored to be part and lead this incredible team!
@OhioStateMedOnc
@OSUCCC_James
@OhioStateMed @drgattimays.bsky.social @stoverlab.bsky.social
Super excited to share the review I wrote with Carolina Reduzzi published in the Journal of Liquid Biopsy on the transformative impact of LB in oncology! 🩸🔬
LB is reshaping cancer care 💥
Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/
@islb.info @christianrolfo.bsky.social @rolfolab.bsky.social
🚨We are hiring Medical Oncologists at @OhioStateMedOnc !
Check the QR code below for the available positions! 3 pathways:
- Physician Scientist
- Clinical Scholar
- Clinical Excellence
Send your applications
@OSUCCC_James @OhioStateMed
Patients with #lungcancer enrolling to Lung-MAP can now be matched to a targeted treatment trial based on prior genomic testing, without submitting new tumor or blood samples, making Lung-MAP 3.0 accessible to more patients at a wider range of clinical sites. #lcsm
www.swog.org/news-events/...
Make the most of your #AACR25 experience with in-person and virtual options, the AACR Runners for Research 5K Run/Walk, a performance by the CheckPoints, and more. Preview highlights in AACR Annual Meeting News: www.aacrmeetingnews.org/news/prepari...
Day 3 at #TexasLung25 diving into diagnostics, #MRD, and #LiquidBiopsy with an outstanding faculty! 🩸🔬
Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social
Exciting discussions shaping the future of #lungcancer testing! 📚
Congrats Roberto! And welcome to @rolfolab.bsky.social !!!
🚨We are hiring Medical Oncologists at @OhioStateMedOnc !
Check the QR code below for the available positions! 3 pathways:
- Physician Scientist
- Clinical Scholar
- Clinical Excellence
Send your applications
@OSUCCC_James @OhioStateMed
Navigating the future of #LiquidBiopsy with @christianrolfo.bsky.social at #poles25
From screening to resistance tracking—MRD is reshaping how we detect, treat, and monitor cancer.
Tissue vs liquid? It’s not a battle—it’s a partnership.
@rolfolab.bsky.social @islb.info @oncoalert.bsky.social
🎉🩸 Thrilled to share that the Journal of Liquid Biopsy is now officially live in PubMed and PMC! A significant step forward for JLB
Check it out here: pmc.ncbi.nlm.nih.gov/journals/?te...
#LiquidBiopsy #PubMed @christianrolfo.bsky.social @yukselurun.bsky.social @eloisajantus.bsky.social
📢 Exciting update in the field of liquid biopsy! A new editorial highlights the essential role of the International Society of Liquid Biopsy (ISLB) in establishing quality framework for LB clinical implementation. 🧬🩸
Read more: doi.org/10.1016/j.crit…
#LiquidBiopsy
@christianrolfo.bsky.social
🚨 Out in @natrevclinoncol.bsky.social
📌ctDNA helps uncover resistance mechanisms
📌Standardized protocols are crucial for improving applications
📌ctDNA + tissue provides a more comprehensive view
nature.com/articles/s41...
@christianrolfo.bsky.social @osucccjames.bsky.social
The HER2 protein is becoming a crucial target not only in breast cancer but also in other tumor subtypes. 🔬✨ Super experts discuss the role of IHC in #lungcancer and #ovariancancer!
@christianrolfo.bsky.social @rolfolab.bsky.social
@osucccjames.bsky.social
#HER2 #IHC #Targettherapy
Diving into the latest on #METex14 skipping #NSCLC, from testing to treatment, with an outstanding panel of experts! 🌟🔬
--> bit.ly/3DFSzLi
Panelists:
@christianrolfo.bsky.social
#UmbertoMalapelle
#YasushiYatabe
#MervatMahrous
Organizer:
#touchOncology
@rolfolab.bsky.social @oncoalert.bsky.social
✨ Insightful presentation by @manelesteller.bsky.social from
@carrerasijc.bsky.social at @osuwexmed.bsky.social
Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊
@christianrolfo.bsky.social @rolfolab.bsky.social
⏱️ To-do list for today: Tune in to the live webinar by
@iaslc.bsky.social covering key highlights from the 2024 Hot Topic in Basic & Translational Science Conference! 🔬🧬 Don't miss out on the latest breakthroughs!
@christianrolfo.bsky.social @rolfolab.bsky.social
www.iaslc.org/meetings-web...
Don't miss the chance to dive into this interesting discussion on lung cancer with an incredible faculty! 🔎🫁💊
#lungcancer
#myESMO
#DeepDiveLungCancer
@christianrolfo.bsky.social @rolfolab.bsky.social
ow.ly/vbSt50UPrrS
Recognizing the brilliant #WomenInMedicine today 2/3/25 who continue to persevere, break glass ceilings and improve healthcare #NWPD25 #IamBlackwell @quirogad.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @maryamlustberg.bsky.social
Amazing group of medical oncologists that I am privileged to work with every day and call friends @stoverlab.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @quirogad.bsky.social @osucccjames.bsky.social
🎯
The ISLB created this survey to understand how to improve the use of #liquidbiopsy in clinical oncology!
Don't miss the opportunity to shape the future of LB in cancer patients!! 🔥
@christianrolfo.bsky.social @robertoboreamd.bsky.social
OSU SABCS meeting - 200 participants in attendance. Great turn out and awesome presentations by our amazing Breast Cancer team. Very proud of them 🙂👏
@OhioStateMedOnc
@StoverLab @quirogad @CherianMathew30 Maggie Gatti-Myes and all team!
#SABCS24
@OSUCCC_James @OhioStateMed
Looking for your first faculty position? Or perhaps new start? THE Ohio State University Comprehensive Cancer Center (Columbus, OH) is hiring in several #MedOnc sections - GI, Thoracic, Breast, Neuroendocrine, cutaneous. #AcademicJobs #OSUCCC @osucccjames.bsky.social @christianrolfo.bsky.social